ArticleCardiovascular and interventional radiology2018
Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Article in Cardiovascular and interventional radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy.Liver research (Beijing, China) · 2026Review
- Risk Stratification and Contemporary Predictors of Survival in Hepatocellular Carcinoma Treated With Transarterial Radioembolization.Gastroenterology research · 2025Article
- Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma.European journal of nuclear medicine and molecular imaging · 2025Article
- Selective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review.Hepatobiliary surgery and nutrition · 2024Review
- The role of biomarkers and dosimetry parameters in overall and progression free survival prediction for patients treated with personalizedEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2023Article
- Improved Survival after Transarterial Radioembolisation for Hepatocellular Carcinoma Gives the Procedure Added Value.Journal of clinical medicine · 2022Article
- TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC.Cardiovascular and interventional radiology · 2022Review
- Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection.European radiology · 2022Article
- Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Improved Tumor Response in Patients on Metformin Undergoing Yttrium-90 Radioembolization Segmentectomy for Hepatocellular Carcinoma.Cardiovascular and interventional radiology · 2021Article
- Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach.Seminars in interventional radiology · 2021Review
- Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?Cardiovascular and interventional radiology · 2021Article
- Correlation and Agreement of Yttrium-90 Positron Emission Tomography/Computed Tomography with Ex Vivo Radioembolization Microsphere Deposition in the Rabbit VX2 Liver Tumor Model.Journal of vascular and interventional radiology : JVIR · 2021Article
- Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models.Seminars in radiation oncology · 2020Review
- History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo identify baseline characteristics and long-term prognostic factors in non-transplant patients with unresectable hepatocellular carcinoma (HCC) who had prolonged survival after treatment with yttrium-90 radioembolization (Y90). MATERIALS AND
methodsSixty-seven "Super Survivors" (defined as ≥ 3-year survival after Y90) were identified within our 1000-patient Y90 database (2003-2017). Baseline imaging and follow-up occurred at 1 month and every 3 months thereafter. Overall survival (OS) was calculated with Kaplan-Meier estimates with log-rank test in subgroups: Child-Pugh (CP) score, distribution of disease, portal vein thrombus (PVT), and technique (segmental vs lobar Y90).
resultsMedian age 69.5 years (range 45-94 years); 69% male; 60% solitary HCC; 79% unilobar disease; 12% PVT; 10% ascites; Barcelona Clinic Liver Cancer Stage A-54%/B-28%/C-16%/D-2%; CP A-70%/B-28%/C-2%. Longest baseline tumor diameter was 5.4 ± 4.0 cm (mean ± SD). All patients had an imaging response (either partial or complete response). Median OS was 67.5 months (95% CI 55.2-82.5). CP score and main PVT stratified median OS (p = 0.0007 and p = 0.0187, respectively). Beyond 3 years, segmental versus lobar Y90 was associated with improved OS with a median OS of 80.2 versus 46.7 months, respectively (p = 0.0024). Dosing > 200 Gy was not a significant predictor of improved OS.
conclusionsSuper Survivors spanning the BCLC staging system maintained durable OS after radioembolization that was stratified by the extent of underlying liver disease. The common variable among all patients was an imaging response. Segmental versus lobar Y90 may have a long-term associated OS benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.